In line with other experimental models of FSGS and clinical FSGS (51–53), serum soluble urokinase plasminogen activator receptor (suPAR) levels increased in mice with experimental FSGS. The gene discussed is PLAUR; the disease is focal segmental glomerulosclerosis.